about
Fusoselect: cell-cell fusion activity engineered by directed evolution of a retroviral glycoprotein.A pathway from chromosome transfer to engineering resulting in human and mouse artificial chromosomes for a variety of applications to bio-medical challengesThe Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) ProteinStructural basis of efficient contagion: measles variations on a theme by parainfluenza viruses.In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines.The microprotein Minion controls cell fusion and muscle formation.Envelope targeting: hemagglutinin attachment specificity rather than fusion protein cleavage-activation restricts Tupaia paramyxovirus tropism.Targeted cell fusion facilitates stable heterokaryon generation in vitro and in vivo.Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies.Human artificial chromosomes for gene delivery and the development of animal modelsRetargeting of microcell fusion towards recipient cell-oriented transfer of human artificial chromosome.Attenuated oncolytic measles virus strains as cancer therapeuticsOncolytic measles viruses for cancer therapy.Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins.Affinity thresholds for membrane fusion triggering by viral glycoproteinsIntegrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.Oncolytic measles virus strains as novel anticancer agents.Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.Engineering oncolytic measles virus to circumvent the intracellular innate immune response.Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.Specific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13.Measles virus for cancer therapy.Ablation of nectin4 binding compromises CD46 usage by a hybrid vesicular stomatitis virus/measles virus.Armed and targeted measles virus for chemovirotherapy of pancreatic cancer.Targeted cell entry of lentiviral vectors.Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents.Use of attenuated paramyxoviruses for cancer therapy.Fighting Cancer with Mathematics and Viruses.Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most EffectiveSyncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.Potential and clinical translation of oncolytic measles viruses.Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread.Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity.Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spreadGlucose-bearing biodegradable poly(amino acid) and poly(amino acid)-poly(ester) conjugates for controlled payload release.Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.Oncolytic measles virus retargeting by ligand displayExploitation of the interaction of measles virus fusogenic envelope proteins with the surface receptor CD46 on human cells for microcell-mediated chromosome transferHeat shock protein inhibitors increase the efficacy of measles virotherapy.
P2860
Q25256213-48E337DA-820A-4F61-9BE9-AB1D58239108Q26824073-11FD0C44-F608-4865-AD91-93BE29AB7BF1Q28069519-57B7CBA5-63F2-46B8-A680-05229AD53110Q30358662-90611BC8-DCAA-4DC0-92DA-79A47F0D17ECQ30832171-CE68E2FF-C17E-4641-A3C3-4C1C5CF0E657Q33112257-8EF4328F-94B9-4730-A007-8BD2BA1A13EDQ33911962-DD0E5686-36AC-403C-A95F-B0D042A22360Q34062386-9E86A94B-429B-4CE7-8A8F-2A11F374FAC9Q34292273-13D015B5-6A98-4E24-A5BA-F2466E5E8BB2Q34542092-42C22E83-A361-4F6F-9D61-EE707C426EDCQ35238272-488C15A2-37DD-471B-8409-882D507D8774Q35667864-5A5586D2-E480-425B-B89F-A1A7C23A933BQ35818876-B8F121DC-9E80-40B8-9407-FF674857F268Q35907056-EAE3254B-4DAE-43DD-83CD-AA4A53BE8C21Q35988675-6EA35150-9DFD-455E-9A5E-A240EC3B4DDCQ36315685-13C4DE26-15EB-40E2-AE14-E824334C81C2Q37115390-12375C5B-64A8-40C7-9F9A-1439EAD0DED0Q37261017-30BAA3A9-C4C7-4707-B34C-DEE88B83F9EDQ37280354-49786821-4A0C-4848-9CF7-7FACD06D3F16Q37324179-4C64A182-DD41-4859-8EF3-3EF2AC46BB3CQ37336713-64125640-48EC-43A8-A1D7-32C0C5718B00Q37358531-2B97DF0A-48CF-41E7-88C1-3B478AD79AD4Q37388577-D2B0D323-5450-4256-9CA1-FC511513B6A8Q37547082-1D959E2B-889F-42AE-966A-0C9EB3BBC1A6Q37557813-6B8E820F-C1A7-4CAF-B96B-870E50568DF3Q37589994-B429C384-C13F-4361-AF47-DF048EC2F7F8Q37628219-90E166F2-5C70-4B69-91A3-B64D0726A399Q37810599-F028DD72-8036-411A-9CED-46DEB13B1A18Q38612646-BCC9EB14-3D5B-44D3-940D-439CE95B417AQ38685020-55F6F163-19FB-4A9F-9B71-17D498E4A603Q38735164-0915244B-51BE-45D9-8864-26C0D4776D1EQ38764947-A328CF91-09F9-4B49-91EC-FB1FFE9C9282Q38791776-984A30D4-260F-467E-A55A-F124ACBADFD0Q38845078-6AC3A72F-07A1-4E1C-A3D1-586B7ED29D6DQ39127778-A05898C3-29F6-4A01-A701-9642E0E11B8FQ39252342-8E19FDBF-E1A2-4E97-A52F-865063813C1EQ39444656-A42FB4B8-BB05-4FF1-89C0-742371DA19D8Q39467959-71C430E7-6D8D-4C9A-8EC8-697EADC5C423Q39707428-1E3BF752-EEE4-4B1A-9A86-D0E7C0708A44Q39999894-613BC583-B3B5-4E67-B1E4-B359E9D5754E
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Antibody-targeted cell fusion.
@en
type
label
Antibody-targeted cell fusion.
@en
prefLabel
Antibody-targeted cell fusion.
@en
P2093
P2860
P50
P356
P1433
P1476
Antibody-targeted cell fusion.
@en
P2093
Hiroyuki Mizuguchi
Mary Harvey
Sompong Vongpunsawad
Takafumi Nakamura
Takao Hayakawa
P2860
P2888
P304
P356
10.1038/NBT942
P577
2004-02-15T00:00:00Z